Madrigal Pharmaceuticals (MDGL) EBT (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly EBT of -$57.1 million for Q2 2026, down 35.17% year-over-year from -$88.1 million in Q2 2025, and up 38.09% quarter-over-quarter from -$92.3 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) EBT (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported EBT for 17 consecutive years, with -$57.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT fell 35.17% year-over-year to -$57.1 million; the TTM figure through Jun 2026 stood at -$432.5 million (down 61.2% YoY), while the FY2025 annual figure was -$853.8 million, up 11.07% from the prior year.
- EBT rose to -$57.1 million in Q2 2026 per MDGL's latest filing, from -$92.3 million in the prior quarter.
- Across five years, EBT topped out at -$42.3 million in Q2 2025 and bottomed at -$172.0 million in Q4 2025.
- Historically, EBT has averaged -$92.7 million across 5 years, with a median of -$85.9 million in 2022.
- On a YoY basis, EBT climbed as much as 72.18% in 2025 and fell as far as 275.12% in 2025.
- Madrigal Pharmaceuticals' EBT stood at -$85.9 million in 2022, then sank by 30.6% to -$112.2 million in 2023, then soared by 59.14% to -$45.8 million in 2024, then tumbled by 275.12% to -$172.0 million in 2025, then soared by 66.77% to -$57.1 million in 2026.
- Business Quant data shows MDGL's EBT at -$57.1 million in Q2 2026, -$92.3 million in Q1 2026, and -$172.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | -57.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.14 Mn |
| Mar 31, 2026 | -92.30 Mn |
| Dec 31, 2025 | -171.98 Mn |
| Sep 30, 2025 | -111.12 Mn |
| Jun 30, 2025 | -42.24 Mn |
| Mar 31, 2025 | -73.24 Mn |
| Dec 31, 2024 | -59.42 Mn |
| Sep 30, 2024 | -106.96 Mn |
| Jun 30, 2024 | -151.97 Mn |
| Mar 31, 2024 | -147.54 Mn |
| Dec 31, 2023 | -112.19 Mn |
| Sep 30, 2023 | -98.74 Mn |
| Jun 30, 2023 | -85.80 Mn |
| Mar 31, 2023 | -76.90 Mn |
| Dec 31, 2022 | -85.91 Mn |
| Sep 30, 2022 | -81.20 Mn |
| Jun 30, 2022 | -70.73 Mn |
| Mar 31, 2022 | -57.52 Mn |
| Dec 31, 2021 | -64.55 Mn |
| Sep 30, 2021 | -63.10 Mn |